Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
81.20
-4.40 (-5.14%)
At close: Mar 27, 2026
TPE:6919 Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 784.44 | 6,901 | 3,422 | 655.05 | 594.91 |
Short-Term Investments | 4,076 | 2,767 | 289.4 | 456.18 | - |
Cash & Short-Term Investments | 4,860 | 9,669 | 3,712 | 1,111 | 594.91 |
Cash Growth | -49.73% | 160.51% | 234.01% | 86.79% | 535.87% |
Accounts Receivable | 6.49 | 5.18 | 7.89 | 3.12 | - |
Receivables | 6.49 | 5.18 | 7.89 | 3.12 | - |
Inventory | 2.88 | 2.86 | 1.02 | 2.81 | 0.05 |
Other Current Assets | 121.55 | 29.12 | 23.16 | 14.87 | 10.32 |
Total Current Assets | 4,991 | 9,706 | 3,744 | 1,132 | 605.27 |
Property, Plant & Equipment | 50.77 | 61.32 | 80.41 | 99.6 | 106.38 |
Long-Term Investments | 4,425 | - | - | - | - |
Other Long-Term Assets | 7.71 | 3.14 | 2.46 | 1.46 | 1.26 |
Total Assets | 9,474 | 9,771 | 3,827 | 1,233 | 712.9 |
Accounts Payable | 1.26 | 0.97 | 1.7 | 2.53 | 0.33 |
Accrued Expenses | 5.05 | 1.97 | - | - | 30.98 |
Current Portion of Long-Term Debt | - | - | - | - | 1.17 |
Current Portion of Leases | 3 | 8.88 | 8.58 | 8.22 | 7.03 |
Current Unearned Revenue | 1.07 | 3.61 | 1.03 | 4.5 | - |
Other Current Liabilities | 35.11 | 37.32 | 62.37 | 33.11 | 0.16 |
Total Current Liabilities | 45.49 | 52.74 | 73.68 | 48.36 | 39.67 |
Long-Term Debt | - | - | - | - | 3.55 |
Long-Term Leases | - | 3 | 11.87 | 20.46 | 25.02 |
Pension & Post-Retirement Benefits | 0.48 | 0.24 | - | - | - |
Other Long-Term Liabilities | 17.68 | 17.71 | - | - | - |
Total Liabilities | 63.66 | 73.7 | 85.55 | 68.82 | 68.24 |
Common Stock | 776.94 | 769.14 | 696.62 | 615.55 | 535.93 |
Additional Paid-In Capital | 8,753 | 9,131 | 3,271 | 834.46 | 217.47 |
Retained Earnings | 80.04 | -56.14 | -227.31 | -286.16 | -107.41 |
Treasury Stock | -130.52 | - | -0.07 | -0.08 | -0.09 |
Comprehensive Income & Other | -68.54 | -147.47 | 0.81 | 0.49 | -1.24 |
Shareholders' Equity | 9,410 | 9,697 | 3,741 | 1,164 | 644.66 |
Total Liabilities & Equity | 9,474 | 9,771 | 3,827 | 1,233 | 712.9 |
Total Debt | 3 | 11.87 | 20.46 | 28.68 | 36.78 |
Net Cash (Debt) | 4,857 | 9,657 | 3,691 | 1,083 | 558.13 |
Net Cash Growth | -49.70% | 161.63% | 240.96% | 93.96% | - |
Net Cash Per Share | 3.15 | 6.75 | 2.98 | 0.92 | 0.61 |
Filing Date Shares Outstanding | 1,553 | 1,538 | 1,393 | 1,231 | 1,072 |
Total Common Shares Outstanding | 1,553 | 1,538 | 1,393 | 1,231 | 1,072 |
Working Capital | 4,946 | 9,653 | 3,670 | 1,084 | 565.6 |
Book Value Per Share | 6.06 | 6.30 | 2.69 | 0.95 | 0.60 |
Tangible Book Value | 9,410 | 9,697 | 3,741 | 1,164 | 644.66 |
Tangible Book Value Per Share | 6.06 | 6.30 | 2.69 | 0.95 | 0.60 |
Machinery | 149.23 | 138.75 | 129.99 | 121.55 | 112.76 |
Construction In Progress | 2.37 | - | 1.14 | 1.82 | 0.3 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.